Drug-eluting stents substantially reduce the incidence of restenosis after percutaneous coronary interventions.) The cytostatic drugs however not only inhibit the proliferation of smooth muscle cell and neointima proliferation but also delay the endothelisation of the stent struts. It may result in persistent inflammatory reaction and also in stent thrombosis. The trials comparing the efficacy of drug-eluting and bare metal stents, and also that of the two drug-eluting stent brands are reviewed. The efficacy of the two brands of drug-eluting stents in prevention of restenosis is almost equal. Late stent thrombosis is more frequent after drug eluting, than after bare metal stents. This rare, but severe complication may develop if drug-eluting stents are used in off-label indications and anatomic situations. In order to avoid late stent thrombosis devices should be used as labelled, the platelet inhibitory treatment should be more efficacious and longlasting than these days. Thorough information about the importance of adherence to prescribed treatment should be delivered to the patients and to the medical community as well.
ASJC Scopus subject areas